Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06220669 · ClinicalTrials.gov registry record · Phase 2
A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis
A Phase 2 study of Multiple Sclerosis, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 200
- Enrollment target
- 20
- Study locations
NCT06220669: Recruiting Phase 2 study of Multiple Sclerosis, sponsored by Eli Lilly and Company.
NCT06220669 is a Phase 2 study of Multiple Sclerosis that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 200 participants, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06220669, a Phase 2 study of Multiple Sclerosis, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 200 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
Primary Outcome
Cumulative number will be measured by magnetic resonance imaging (MRI) scans.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY3541860
Study Locations (20)
Florida
- Healthcare Innovations Institute, LLC - Coral Springs
- Royal Palm Medical Group - Fort Myers
- Eastern Medical Group Research - Fort Myers
- Panhandle Research and Medical Clinic - Gulf Breeze
- High Quality Research - Miami
- USF MS Center - Tampa
- Conquest Research LLC - Winter Park - ClinEdge - PPDS - Winter Park
Other
- Centre Hospitalier Universitaire de Clermont Ferrand - Clermont-Ferrand
- CHRU de Nancy - Nancy
- CHU Gui De Chauliac - Nîmes
- Centre Hospitalier Intercommunal - Site de Poissy - Poissy
Texas
- ANRC Research - El Paso
- Prolato Clinical Research Center - Houston
- 1960 Family Practice, PA - Houston
Missouri
- Sharlin Health and Neurology - Ozark
- Psych Care Consultants Research - St Louis
Illinois
- Consultants in Neurology - Northbrook
South Carolina
- Premier Neurology - Greer
Tennessee
- Hope Neurology - Knoxville
Washington
- Swedish Multiple Sclerosis Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2024-03-19 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What NCT06220669 shows while recruiting
NCT06220669 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 584-participant average among 315 other Multiple Sclerosis trials with a reported enrollment target (66% lower).
The record links to 1 condition, with Multiple Sclerosis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06220669 names 20 study sites across 8 states, led by Florida, Other, Texas.
Frequently Asked Questions
What is clinical trial NCT06220669 about?
NCT06220669 is a clinical study titled "A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis". The main purpose of this study is to evaluate the safety and efficacy of LY3541860 in adult participants with multiple sclerosis that gets worse and gets better. The study will last about 9 months with additional 6 months follow-up.
What is the current status of trial NCT06220669?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 200 participants. The study started on 2024-03-19. Estimated completion is 2028-08.
What conditions does trial NCT06220669 study?
This clinical trial studies the following conditions: Multiple Sclerosis.
What interventions are being tested in trial NCT06220669?
The interventions under investigation include: Placebo (DRUG), LY3541860 (DRUG).
Who is sponsoring clinical trial NCT06220669?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06220669 being conducted?
This trial has 20 study locations across Florida, Illinois, Missouri, South Carolina, Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06220669's enrollment target sits among peer trials
200 77th of 315 higher than 237 of 315 other Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Cannabidiol in Persons With MS: the Role of Sleep and Pain Phenotype
RECRUITING · Phase 2
-
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
RECRUITING · Phase 2
-
Solriamfetol for the Treatment of Multiple Sclerosis Fatigue
RECRUITING · Phase 2
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
RECRUITING · Phase 2
-
Efficacy of Cognitive Behavioral Therapy for Insomnia to Treat Insomnia Symptoms in Individuals With Multiple Sclerosis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI